Showing results (271-280 of 793) with videos related to

Sort By:
Pageof 80
Pharmacotherapy|February 5, 2022
Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantAkhilesh Sivakumar, Evan B Bryson, Kevin H Hall, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 15, 2013
Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myelomaR Donald Harvey, Jonathan L Kaufman, Heather R Johnson, et al.
Nucleic Acids Research|December 31, 2005
ProTherm and ProNIT: thermodynamic databases for proteins and protein-nucleic acid interactionsM D Shaji Kumar, K Abdulla Bava, M Michael Gromiha, et al.
Blood Cancer Journal|May 25, 2026
Prevalence of monoclonal gammopathy of undetermined significance (MGUS) using a sensitive mass spectrometry assay in young individuals 10-49 years of age: a population-based study from the National Health and Nutritional Examination SurveyShaji Kumar, David Murray, Dirk R Larson, et al.
American Journal of Hematology|March 18, 2021
Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic reviewGhulam Rehman Mohyuddin, Kelly Koehn, Al-Ola Abdallah, et al.
The Oncologist|April 1, 2023
Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed MyelomaRafael Fonseca, Thierry Facon, Mahmoud Hashim, et al.
Clinical Nephrology|December 19, 2017
High-dose melphalan and autologous hematopoietic stem cell transplant in patient with C3 glomerulonephritis associated with monoclonal gammopathyNicola Lepori, Wisit Cheungpasitporn, Sanjeev Sethi, et al.
Cancer|October 18, 2018
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agentsRoberto Mina, Nisha S Joseph, Jonathan L Kaufman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2017
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple MyelomaDan T Vogl, Noopur Raje, Sundar Jagannath, et al.
Future Oncology (London, England)|May 10, 2025
EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myelomaSagar Lonial, Meletios A Dimopoulos, Jesus G Berdeja, et al.
Pageof 80